乳腺癌组织细胞体外对化疗药物敏感性检测结果与GST-π Topo Ⅱ表达的关系  

Correlation of GST-π and Topo Ⅱ Expression with the Chemosensitivity of Human Breast Cancer Cells in vitro

作　　者：杨峂[1] 和钢[1] 傅庆国[1] 俞吉霞[2] 黄蓉[2] 李克强[3] 

机构地区：[1]浙江省宁波市第二医院肿瘤外科,浙江省宁波市315010 [2]浙江省宁波市第二医院病理科,浙江省宁波市315010 [3]浙江省宁波市第二医院中心实验室,浙江省宁波市315010

出　　处：《中国肿瘤临床》2011年第4期185-188,共4页Chinese Journal of Clinical Oncology

基　　金：宁波市科技局农业与社会发展科研项目基金(编号:2007C10017);宁波市医学科学重点项目基金资助(编号:2006004)

摘　　要：目的:探讨乳腺癌组织细胞体外对化疗药物敏感性检测结果(ATP-TCA法)与GST-π、Topo Ⅱ表达的关系。方法:用ATP-TCA法检测45例乳腺癌标本对4种常用化疗单药表阿霉素(EPI)、紫杉醇(PTX)、多西紫杉醇(TXT)、吉西他滨(GEM)及2种联合用药表阿霉素+多西紫杉醇(EPl+TXT)和环磷酰胺+表阿霉素+5-氟尿嘧啶(CEF)的敏感性,并用免疫组化方法检测乳腺癌组织GST-π、TopoⅡ的表达。结果:ATP-TCA检测结果显示,表阿霉素、紫杉醇、多西紫杉醇、吉西他滨体外对乳腺癌细胞增殖抑制率分别为62.2%、35.6%、8.9%、15.6%;联合用药EPI+TXT、CEF的抑制率分别是77.8%、73.3%,高于单药紫杉醇、多西紫杉醇、吉西他滨,有显著性差异,P<0.01。45例乳腺癌标本中GST-π阳性表达率为44.4%(20/45),TopoⅡ阳性表达率为62.2%(28/45)。在GST-π表达阴性或Topo Ⅱ表达阳性时,表阿霉素、EPI+TXT及CEF方案对乳腺癌组织细胞增殖抑制率较高,有显著性差异,P<0.01。结论:ATP-TCA法结合GST-π、TopoⅡ的表达可用于乳腺癌化疗药物的选择。Objective： To investigate the correlation of GST-π and TopoⅡ expression with the chemosensitivity of breast cancer cells in vitro. Methods： ATP-tumor chemosensitivity assay （ ATP-TCA ） was used to determine the effect of 4 single chemotherapeutics [Epirubicin （ EPI ）, Paclitaxel （ PTX ）, Taxotere （ TXT ）, and Gemcitabine （ GEM ） ] and 2 combined regimens [ Epirubicin ＋ Taxotere （EPI ＋ TXT ）, Cyclophosphamide ＋ Epirubicin ＋ 5-Fluorouracil （ CEF ） ] of in vitro breast cancer cells from 45 breast cancer patients. Expression of GST-π and Topo Ⅱ was examined by immunohistrochemistry. Results： ATP-TCA showed that the inhibitory rates of EPI, PTX, TXT and GFM for breast cancer cell growth were 62.2 %, 35.6 %, 8.9 %, and 15.6 %, respectively. The inhibitory rates of EPI＋TXT and CEF were 77.8 % and 73.3 %, respectively, higher than those of PTX, TXT, and GEM （ P〈 0.01 ）. Immunohistochemistry showed that the expression rates of GST-π and Topo Ⅱ were 44.4 % （ 20/45 ） and 62.2 % （ 28/45 ）, respectively. EPI, EPI＋TXT and CEF showed higher inhibitory rate in cases with Topo Ⅱ expression or in cases without GST-n expression （ P 〈 0.01 ）. Conclusion： ATP-TCA combined with detection of GST-π and Topo Ⅱ expression can be used to screen effective therapeutics against breast cancer.

关 键 词：乳腺癌 化疗敏感性 谷胱甘肽S转移酶-Π DNA拓扑异构酶Ⅱ 

分 类 号：R737.9[医药卫生—肿瘤]